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Abstract 
Purpose: The purpose of this study was to evaluate the impact of sugammadex on operating room (OR) times versus neostigmine in 
patients recovering from rocuronium or vecuronium induced neuromuscular blockade. 
Methods: This retrospective cohort study evaluated patients 18 years or older with an American Society of Anesthesiologists (ASA) 
physical status of I-III who received sugammadex or neostigmine (January- October 2017) for reversal of rocuronium or vecuronium at 
a 500 bed, community hospital. Patients who were pregnant or breastfeeding were excluded. The primary outcome measure was the 
time from sugammadex or neostigmine administration to OR exit. The primary outcome was evaluated using a linear regression model 
adjusting for inpatient procedures, age, sex, body mass index, and ASA score. Secondary outcomes included the incidence of 
bradycardia as well as nausea and vomiting. 
Results: The baseline characteristics of the patients in the cohort (sugammadex=134, neostigmine=143) were similar. The median time 
from drug administration to OR exit was similar for neostigmine and sugammadex (16 vs. 15.5 minutes, p=0.11). Sugammadex had a 
statistically significant reduction in time from drug administration to OR exit (coefficient -2.7 minutes, 95% confidence interval -5.2 to 
-0.2 minutes) in the multivariable linear regression model. Sugammadex had lower rates of bradycardia (5.6 vs. 2.2%) or nausea and 
vomiting (18 vs. 11%) that did not reach statistical significance. 
Conclusions: Sugammadex had statistically shorter OR exit times after drug administration in the cohort. The mean 2.7 minute benefit 
is unlikely to be clinically meaningful and limits its application in practice unless larger cohorts detect a benefit due to a significant 
reduction.in.adverse.events. 
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Introduction 
The United States (US) Food and Drug Administration approved 
sugammadex in 2015. This is significant as sugammadex is the 
first new agent in decades for neuromuscular blocker (NMB) 
reversal in the US. A meta-analysis reported that sugammadex 
produced quicker reversal of NMB (10.2 minutes) along with 
decreased risks of bradycardia (RR 0.6, 95%CI 0.07 to 0.34), 
postoperative nausea and vomiting (RR 0.52, 95%CI 0.28-0.97), 
and postoperative residual paralysis (RR 0.40, 95%CI 0.28 to 
0.57) when compared to neostigmine.1 Another meta-analysis 
reported faster discharge times from the operating room (OR) 
(mean difference 22 minutes) and the post-anesthesia care unit 
(PACU) (mean difference 17 minutes) for sugammadex when 
compared with neostigmine.2 However, the application of 
these findings into routine clinical practice are limited by the 
drug acquisition costs of sugammadex and whether these 
reductions in OR times can be replicated in community hospital 
settings. Potential reasons for differences in sugammadex’s 
effectiveness between community and the data from 
randomized, controlled trials in academic hospitals include the 
types of surgical cases, staffing levels, and/or monitoring 
protocols. 
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The meta-analysis suggesting quicker OR and PACU discharge 
times with sugammadex compared with neostigmine included 
very few studies with limited numbers of patients.2 Specifically, 
the time to OR discharge analysis was only able to use two of 
the six included studies (n = 108) and the PACU discharge 
analysis used four studies (n = 353). This meta-analysis included 
only randomized controlled trials. While randomized controlled 
trials are the gold standard of evidence-based medicine, they 
may not reflect a drug’s effectiveness in a community hospital 
setting. Randomized, controlled trials have rigorous protocols 
and are often conducted in large, academic medical centers 
that do not share many characteristics with community 
hospitals. This means that we do not know how much of 
sugammadex’s beneficial adverse event profile and shorter OR 
times will translate into routine surgical practice. If these 
findings can be replicated in the community hospital setting, 
then sugammadex may be beneficial as it would decrease costs 
related to OR times and adverse events. 
 
This study was conducted to determine if sugammadex would 
produce shorter OR times compared to neostigmine for NMB 
reversal in a community hospital that performs a wide variety 
of elective and non-elective procedures. We addressed this 
question by conducting a retrospective cohort study of 
sugammadex versus neostigmine in patients receiving NMB for 
a surgical procedure at a community hospital. We hypothesized 
the use of sugammadex would result in shorter times from 
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administration of the NMB reversal agent to OR exit than 
neostigmine. 
  
Materials and Methods 
This retrospective cohort study included patients who 
underwent a surgical procedure at a 500-bed community 
hospital from January 1, 2017 to October 31, 2017. Anesthesia 
was induced and maintained as decided by the 
anesthesiologist. After induction, the NMB agent was 
administered and was followed by intubation. Doses of NMB 
agent were administered intra-operatively as deemed clinically 
appropriate by the anesthesiologist. The patient was extubated 
and discharged to the PACU following administration of the 
NMB reversal agent. Discharge from the PACU occurred when 
the modified Aldrete score was 9 or 10 and the anesthesiologist 
approved PACU discharge.3  This investigator-initiated study 
was approved on 13 November 2017 by the Western 
Institutional Review Board (approval number 20172660). 
 
Eligible patients received rocuronium or vecuronium as NMB 
and received neostigmine or sugammadex for reversal. Patients 
were included in the study if they appeared on the electronic 
medical record list of surgical cases.  Data were abstracted from 
the electronic medical record system (including scanned paper 
charts). Patients less than 18 years of age and pregnant or 
breastfeeding women were excluded. Patients with an 
American Society of Anesthesiologists (ASA) physical status 
classification score of IV or greater were also excluded.4 The 
inclusion of patients with life-threatening conditions (ASA IV) 
would have likely increased the variability in OR and/or PACU 
times due to factors unrelated to the choice of NMB reversal 
agent. 
 
We collected the following data: demographic information, 
vitals, ASA scores, time to discharge from the OR, time to 
discharge from the PACU, bradycardia, and post-operative 
nausea and/or vomiting (PONV). The dose, agent used, and 
administration times of the NMB and reversal agent were also 
collected. 
 
The primary outcome was defined as time from sugammadex 
or neostigmine administration to OR exit. OR exit was defined 
as the wheels of the patient’s bed exiting the OR in transport to 
the PACU. Secondary outcomes included overall OR time, 
overall PACU time, time from reversal agent administration to 
PACU discharge, as well as the incidence of bradycardia or 
PONV. Chi-squared test and Fisher’s exact test were used as 
appropriate for nominal data. The Mann-Whitney U test was 
used for continuous and ordinal data. Continuous data were 
assumed to be non-normally distributed. Mulitvariable linear 
regression models were also constructed adjusting for inpatient 
procedures, age, sex, body mass index, and ASA score.  An alpha 
of 0.05 was utilized for significance testing. All analyses were 
conducted using Stata 15.1 (College Station, TX). 
 
 
Results  
The cohort included 277 patients (neostigmine = 143, 
sugammadex = 134) after applying the inclusion/exclusion 
criteria. Reasons for cohort exclusion were the following: ASA 
score of IV or greater (n = 56), spontaneous recovery (n = 38), 
incomplete records (n =10), pregnancy (n =3), and age < 18 
years (n = 3). The types and numbers of surgical procedures are 
provided in the supplementary tables. Baseline characteristics 
including age, sex, weight, height, and ASA score were similar 
for both groups (Table 1). The sugammadex group received 
rocuronium more often for NMB (15% vs. 6%, p = 0.02). Patients 
who received neostigmine were administered a median dose of 
4 mg (interquartile range [IQR] 3, 5), which is 0.043 mg/kg (IQR 
0.031, 0.054). All patients who received neostigmine also 
received glycopyrrolate at a median dose of 0.044 mg/kg (IQR 
0.031, 0.058). Patients who received sugammadex were 
administered a median dose of 200 mg (IQR 150, 200), which is 
2.06 mg/kg (IQR 1.87, 2.33).  
 
The median time from NMB reversal agent administration to OR 
discharge was similar for both neostigmine and sugammadex 
(16 vs. 15.5 minutes, p=0.23), Table 2.  Male sex was the only 
factor significantly associated with time from NMB reversal 
agent administration to OR discharge in the univariable analysis 
(p = 0.02). Analysis of total OR time (108 vs. 104.5 minutes, p= 
0.11), total PACU time (113 vs. 113.5 minutes p=0.58), and time 
from NMB reversal agent administration to PACU discharge 
(130 vs. 129.5 minutes, p= 0.33) were similar for both groups. 
 
Time from sugammadex administration to OR discharge was 
significantly shorter in the linear regression model (mean 
difference -2.7 minutes, 95%CI -5.2 to -0.2 minutes), Table 3. 
The model included adjustments for inpatient procedures, age, 
male sex, body mass index, and ASA score. No other factors 
included in the model were associated with time from NMB 
reversal agent administration to OR discharge. Total PACU time 
was shorter with sugammadex in the multivariable model, but 
the estimate was imprecise given the wide confidence interval 
(mean difference -10.0 minutes, 95%CI -26.3 to 6.4 minutes). 
Inpatient surgical procedures were associated with total PACU 
time in the model (mean difference 25.5 minutes, 95%CI 8.6 to 
42.5 minutes). 
 
The frequency side effects collected in the cohort were 
statistically similar between both groups. Sugammadex had 
numerically lower incidence of bradycardia (5.6% vs. 2.2%, OR 
0.39, 95%CI 0.11 to 1.38) and PONV (17.5% vs. 11.3%, OR 0.60, 
95%CI 0.30 to 1.19). No patients in either group experienced 
refractory NMB.  
 
Discussion 
This study was designed to determine whether sugammadex 
produced shorter times from NMB reversal agent 
administration to OR discharge than neostigmine. Sugammadex 
reduced adjusted OR discharge times after reversal agent 
administration by three minutes. Sugammadex did not provide 
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a statistically significant decrease in total PACU time, PONV, or 
bradycardia even though each of these outcomes numerically 
favored sugammadex. 
 
The results suggesting shorter OR exit times with sugammadex 
were unable to be replicated in the community hospital 
studied. This may be due to the wide variety of surgeries 
represented in the study cohort. We included both elective and 
non-elective procedures unlike randomized controlled trials. 
The study cohort also had several orthopedic and women’s 
health related surgeries that are not included in studies 
analyzed by previous meta-analyses. A recent meta-analysis of 
two randomized controlled trials (n=282) also found 
sugammadex shortened OR discharge times by six minutes.2 
One of the studies only evaluated elective procedures and the 
other only evaluated appendectomies or laparoscopic 
cholecystectomies. 
 
A retrospective audit was conducted to evaluate the impact of 
restricting sugammadex on clinical outcomes. Sugammadex 
had been used in the institute unrestrictedly due to superior 
reversal and subsidized cost, but upon removal of cost 
subsidies, guidelines were developed for the state wide use of 
sugammadex in a restricted manner. This study, (n=2649) of 
unrestricted and restricted sugammadex also found no 
difference in total OR time (135 vs. 137 minutes, p = 0.14) 
similar to the findings of the present study.5 This study 
evaluated patients who underwent a wide variety of surgical 
procedures, similar to this cohort. The study did not evaluate 
the impact of sugammadex restriction on time from NMB 
reversal agent to OR discharge. The meta-analysis by Carron et 
al found that sugammadex shortened total OR time by a mean 
difference of 22 minutes. This analysis included fewer patients 
(n=108) than the current cohort.2 
 
The results of the present study agree with others suggesting 
that sugammadex has shorter total PACU times, but the 
multivariable model was too imprecise to demonstrate 
statistical significance. This is in part due to the small sample 
size of the study cohort and a lower mean difference in total 
PACU time than previous studies. All four individual studies in 
the Carron et al meta-analysis (n = 353) found shorter PACU 
times with sugammadex.2 The magnitude and precision of this 
finding was highly dependent on the model used. A fixed effect 
model (mean difference 32 minutes, 95%CI 30.6 to 33.0 
minutes) showed a greater impact of sugammadex than a 
random effects model (mean difference 17 minutes, 95%CI 0.23 
to 33.7 minutes). Similarly, Rao Kadam and Howell found that 
unrestricted sugammadex use shortened PACU time by 19 
minutes (p < 0.0001).5 This study’s findings were most similar to 
total PACU times observed in the present study. This is likely 
due to the inclusion of multiple surgical types. Carron and 
colleagues found similar times from NMB reversal agent 
administration to PACU discharge for both agents.2 
 
The rates of PONV and bradycardia were numerically lower for 
sugammadex in this study’s cohort. The differences did not 
reach the level of statistical significance. Hristovska and 
colleagues found a significantly lower incidence of bradycardia 
(n = 1218; RR 0.16, 95%CI 0.07 to 0.34) and PONV (n = 389; RR 
0.52, 95%CI 0.28 to 0.97). The authors did not report absolute 
incidence for these adverse events.1 Rao Kadam and Howell 
observed similar rates of nausea for both agents (p = 0.57). The 
authors did not evaluate vomiting or bradycardia.5 The rate of 
nausea (2.2%) they observed was much lower than this study’s 
cohort. 
 
The routine clinical use of sugammadex for NMB reversal in all 
surgical patients is not justified by the findings from this cohort. 
The cost of sugammadex for 100 patients is approximately 
$9,200 (US Dollar) at the study institution. The three minutes of 
OR time gained by using sugammadex is unlikely to be sufficient 
to allow any extra surgical cases per day. At the study 
institution, operating room time cost to the facility per minute 
ranges from $9-15 per minute depending on the level of acuity. 
For 100 patients, saving 270 minutes of OR time would result in 
savings of $2,430-4,050. The small absolute differences in rates 
of PONV and bradycardia are also unlikely to result in sufficient 
cost savings to justify routine sugammadex use in a broad 
population like the current cohort. Specifically, the 6.2% 
absolute difference in PONV found in this study would result in 
an estimated increased cost of $465 (US Dollar) associated with 
neostigmine per 100 patients ($75 per patient times 6.2% 
increased risk of PONV).6 
 
A significant limitation of the present analysis is the lack of 
Train-of Four monitoring. This made it impossible to judge the 
depth of NMB produced or whether or not patients achieved 
complete reversal upon OR exit or PACU discharge. There is a 
growing emphasis on having mandatory Train-of Four 
monitoring for all patients undergoing surgical procedures 
involving NMB. We utilized patients who underwent 
procedures in 2017, prior to the publication of the consensus 
document from the International Anesthesia Research Society 
and the Canadian Anesthesiologists’ Society guidelines 
recommending quantitative monitoring in all patients receiving 
NMBs.7,8 The American standards remain silent on this issue to 
date.9 
 
The generalizability of this study is also limited by being a small, 
single center, retrospective evaluation that is subject to 
measured and unmeasured confounding. This study may have 
more external validity than randomized clinical trials of 
sugammadex. This is because the study cohort included a wide 
variety of procedures and few exclusion criteria. Discharge 
planning or transfer plans may have influenced PACU times. The 
median neostigmine doses in the study cohort were lower than 
all but one trial cited by the Carron et al meta-analysis. This may 
have accentuated the effectiveness of sugammadex while 
minimizing its safety advantages. The lower neostigmine doses 
may also represent few patients receiving deep NMB. Reversal 
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of deep NMB may be an area where sugammadex has a greater 
impact on outcomes.2 The study’s small sample size also 
affected the precision of the estimates regarding 
sugammadex’s impact on adverse events. A larger study may 
have found a statistically significant difference. More patients 
received vecuronium with sugammadex in this cohort (n = 114) 
than all previous trials combined in a 2017 meta-analysis (n = 
74).10 We did not find any impact of vecuronium on the time to 
OR or PACU discharge. This is not surprising based on a similar 
duration of action reported for rocuronium (0.6-0.9 mg/kg) and 
vecuronium (0.1 mg/kg) in a randomized study of rapid-
sequence induction of anesthia.11. 
 
NMB reversal agent administration to OR discharge times were 
better with sugammadex than neostigmine for surgical 
patients. This difference was not clinically meaningful in the 
study cohort and was shorter than previously reported by other 
meta-analyses. This conclusion is limited by the dose of 
neostigmine being lower than the dose used in other studies, 
other factors that could affect OR or PACU discharge, and the 
potential variability of charting adverse events. We recommend 
using neostigmine for most surgical patients despite the 
limitations of this trial since sugammadex did not produce a 
meaningful improvement in the study cohort. Confirmatory 
studies are needed. 
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Table 1: Baseline characteristics 
Characteristic Neostigmine 
(n = 143) 
Sugammadex 
(n = 134) 
p-value 
Age 56 (39, 69) 58 (37, 72) 0.56 
Male (%) 39.2 48.5 0.12 
Height (meters) 1.7 (1.6, 1.78) 1.69 (1.63, 1.78) 0.42 
Weight (kilograms) 88 (72, 101) 84.5 (72, 98) 0.25 
BMI (kg/m2) 30.1 (25.7, 35.9) 28.4 (25, 33.5) 0.06 
Neuromuscular blocker used (%)   0.02 
Rocuronium 6.3 14.9  
Vecuronium 93.4 85.1  
Inpatient surgery (%) 51.8 53.0 0.84 
ASA score (%)   0.31 
I 2.8 6.0  
II 54.6 57.5  
III 42.7 36.6  
Data presented as median (interquartile range) unless otherwise noted. 
 
 
 
Table 2: Univariable analysis of time from drug administration to leaving the operating room 
Characteristic No Yes p-value 
Sugammadex 16 (11, 23) 15.5 (11, 20) 0.23 
Age 60 years or greater 16 (12, 21) 16 (10.5, 21) 0.77 
Male 15 (10, 20) 17 (14, 22) 0.02 
Height 1.7 meters or greater 15 (10, 20) 17 (13, 22) 0.09 
Weight 80 kilograms or greater 16 (10, 20) 16 (12, 21) 0.14 
BMI 30 kg/m2 or greater 17 (11, 20) 15.5 (12, 21) 0.77 
Rocuronium 16 (11, 20.5) 16 (11, 22) 0.65 
Inpatient surgery 17 (11, 21) 15.5 (11.5, 20) 0.51 
ASA score   0.78 
I  17.5 (14, 20)  
II  16 (12, 21)  
III  16 (10, 21)  
Data presented as median (interquartile range) unless otherwise noted. 
 
 
 
Table 3. Multivariable linear regression analyses evaluating the  
impact of sugammadex on time in the operating room or post-anesthesia care unit 
 Time from drug 
administration to leave 
operating room (minutes) 
Total time in post-anesthesia 
care unit (minutes) 
Characteristic Coefficient (95% Confidence 
Interval) 
Coefficient (95% Confidence 
Interval) 
Inpatient procedure -1.7 (-4.4 to 0.9) 25.5 (8.6 to 42.5) 
Age (per one year 
increment) 
0.0 (-0.1 to 0.1) 0.1 (-0.5 to 0.6) 
Male sex 2.2 (-0.3 to 4.8) -3.4 (-19.9 to 13.1) 
Body mass index (per 1 
kg/m2 increment) 
0.4 (-0.1 to 0.2) 0.8 (-0.2 to 1.8) 
ASA score -1.1 (-3.7 to 1.5) 10.7 (-6.1 to 27.4) 
Sugammadex -2.7 (-5.2 to -0.2) -10.0 (-26.3 to 6.4) 
 
